RecruitingPhase 2ACTRN12605000369628
A Double-Blind, Randomised, Single Centre, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of a Single Subcutaneous Implant of EPT 1647 in Patients Suffering from Recurrent Polymorphous Light Eruption
Sponsor
Epitan Limited
Enrollment
30 participants
Start Date
Sep 12, 2005
Study Type
Interventional
Conditions
Eligibility
Sex: Both males and females
Inclusion Criteria1
- History of PMLE.
Exclusion Criteria1
- History of skin cancer.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
EPT1647 - 6 months
EPT1647 - 6 months
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000369628